Advertisement

Topics

HiFiBiO Therapeutics Company Profile

06:24 EST 19th November 2018 | BioPortfolio

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to address unmet medical needs around the world through open-innovation partnerships with industry and academia. The company features a strong global footprint with cutting-edge laboratories on three continents in Cambridge, Mass., Paris, France, and Shanghai, China. For more information, please visit www.hifibio.com.


News Articles [743 Associated News Articles listed on BioPortfolio]

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...

HiFiBio acquires H-Immune Therapeutics

HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapies. Financial terms were not disclosed.

Kite partners with HiFiBiO Therapeutics for TCR-based cancer therapies

Gilead Sciences’ subsidiary Kite has signed a research collaboration and licence agreement with biotechnology company HiFiBiO Therapeutics to help develop...Read More... The post Kite partners with ...

Kite, HiFiBiO Therapeutics to develop technology for discovery of TCRs to treat cancer

Kite and HiFiBiO intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR The post Ki...

HiFiBiO Therapeutics raises $37.5m in Series B funding

HiFiBiO Therapeutics has secured $37.5m Series B financing to accelerate pipeline of antibody drugs to treat cancer and autoimmune disorders.

HiFiBiO Forms Drug Discovery Partnership with Takeda

HiFiBiO Therapeutics, a US-France-Hangzhou antibody discovery company, formed a multi-target partnership with Takeda Pharma. HiFiBiO discovers therapeutic antibodies through single-B-cell screening, u...

HiFiBiO Forms Cell Therapy Discovery Collaboration with Kite Pharma

HiFiBiO Therapeutics, a US-France-China biopharma, will collaborate with Kite Pharma, a division of Gilead Sciences to develop technology that supports the discovery of neoantigen-reactive T cell rece...

Boston's HiFiBiO Raises $37.5 Million from China Investors

HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, closed a $37.5 million Series B financing led by two China investors, Sequoia Capital and Lyfe Capital. According to Hi...

PubMed Articles [466 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [162 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1272 Associated Companies listed on BioPortfolio]

HiFiBiO Therapeutics

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological exper...

HiFiBiO SAS

HiFiBiO SAS is advancing an innovative and integrated discovery engine that creates unparalleled opportunities for discovering novel, differentiated therapeutic antibodies against...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "HiFiBiO Therapeutics" on BioPortfolio

We have published hundreds of HiFiBiO Therapeutics news stories on BioPortfolio along with dozens of HiFiBiO Therapeutics Clinical Trials and PubMed Articles about HiFiBiO Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HiFiBiO Therapeutics Companies in our database. You can also find out about relevant HiFiBiO Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record